FLUKE JOHN M JR 4
4 · Athira Pharma, Inc. · Filed Sep 22, 2020
Insider Transaction Report
Form 4
FLUKE JOHN M JR
Director
Transactions
- Conversion
Common Stock
2020-09-22+6,731→ 6,731 total(indirect: By Fluke Capital Management, L.P.) - Conversion
Common Stock
2020-09-22+12,610→ 63,050 total - Conversion
Common Stock
2020-09-22+51,831→ 114,881 total - Conversion
Series A-1 Preferred Stock
2020-09-22−51,831→ 0 total→ Common Stock (51,831 underlying) - Conversion
Series B-1 Preferred Stock
2020-09-22−6,731→ 0 total(indirect: By Fluke Capital Management, L.P.)→ Common Stock (6,731 underlying) - Conversion
Series A Preferred Stock
2020-09-22−12,610→ 0 total→ Common Stock (12,610 underlying)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- [F2]Each share of Series A-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- [F3]Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.